<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01408121</url>
  </required_header>
  <id_info>
    <org_study_id>AA Genetic</org_study_id>
    <nct_id>NCT01408121</nct_id>
  </id_info>
  <brief_title>African-American Pharmacogenetics</brief_title>
  <acronym>AA Genetic</acronym>
  <official_title>African-American Pharmacogenetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a genetic and platelet reactivity study of African-American versus Caucasian patients&#xD;
      undergoing percutaneous coronary intervention and receiving clopidogrel or prasugrel. The&#xD;
      investigators aim is twofold: to describe differences in allele frequencies between&#xD;
      African-Americans and Caucasians, and to explore associations of platelet reactivity and&#xD;
      genetic polymorphisms in these two groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a pharmacogenetic cohort study of 100 African-American versus 100&#xD;
      Caucasian patients presenting with an acute coronary syndrome, receiving clopidogrel or&#xD;
      prasugrel and undergoing PCI. The study will have four arms: African-American on clopidogrel;&#xD;
      African-American on prasugrel; Caucasian on clopidogrel; and Caucasian on prasugrel. All&#xD;
      patients will undergo genotyping and platelet reactivity testing with the VerifyNow P2Y12&#xD;
      assay, at least 6 hours after receiving a thienopyridine loading dose, but before hospital&#xD;
      discharge. All patients will be treated with aspirin 325 mg/day as well.&#xD;
&#xD;
      Race determination will be based on a patient's self-report, but patients enrolled in the&#xD;
      trial must also report that all four of their grandparents were of the same race as theirs.&#xD;
      Other races (Asian, Native American, et al) will be excluded from this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Distribution of CYP polymorphisms</measure>
    <time_frame>During hospital stay; average hospital stay is less than 48 hours</time_frame>
    <description>CYP polymorphisms will be classified by their known effects upon enzyme function, using the consensus star-allele nomenclature. More specifically, patients will be classified as a &quot;poor metabolizer&quot; if they possess at least one CYP allele known to be associated with reduced function of that particular CYP enzyme. Allele frequencies will then be compared between African-american and Caucasian patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity</measure>
    <time_frame>During hospital stay; average hospital stay is less than 48 hours</time_frame>
    <description>The secondary exploratory objective is to assess for associations between &quot;poor metabolizer&quot; CYP genotypes and the levels of post-thienopyridine platelet reactivity.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>African-American on clopidogrel</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>African-American on prasugrel</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Caucasian on clopidogrel</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Caucasian on prasugrel</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay</intervention_name>
    <description>All patients will undergo genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay, at least 6 hours after receiving a thienopyridine loading dose but before hospital discharge.</description>
    <arm_group_label>African-American on clopidogrel</arm_group_label>
    <arm_group_label>African-American on prasugrel</arm_group_label>
    <arm_group_label>Caucasian on clopidogrel</arm_group_label>
    <arm_group_label>Caucasian on prasugrel</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        African-american versus Caucasian patients undergoing percutaneous coronary intervention&#xD;
        and receiving clopidogrel or prasugrel.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients age 18 or older, of both genders&#xD;
&#xD;
          2. Presenting with an ACS, defined as at least two of the following:&#xD;
&#xD;
               -  symptoms consistent with myocardial ischemia;&#xD;
&#xD;
               -  ST segment elevation or depression of at least 1 mm in 2 or more contiguous leads&#xD;
                  on EKG;&#xD;
&#xD;
               -  a cardiac troponin I level above upper limit of normal.&#xD;
&#xD;
          3. Self-reported African-american or Caucasian race&#xD;
&#xD;
             a. all 4 grandparents of same race&#xD;
&#xD;
          4. No contraindications to prasugrel therapy.&#xD;
&#xD;
          5. Patient is scheduled for, or has already undergone, PCI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergies to aspirin, clopidogrel, or prasugrel.&#xD;
&#xD;
          2. Patient known to be pregnant or lactating.&#xD;
&#xD;
          3. Patient with known history of bleeding diathesis or currently active bleeding.&#xD;
&#xD;
          4. Platelet count &lt;100,000/mm at the time of enrollment.&#xD;
&#xD;
          5. Hematocrit &lt;25% at the time of enrollment.&#xD;
&#xD;
          6. On warfarin therapy at the time of PCI, or patient likely to require warfarin therapy&#xD;
             post-PCI.&#xD;
&#xD;
          7. Received fibrinolytics within the past 48 hours.&#xD;
&#xD;
          8. Received a glycoprotein IIb/IIIa inhibitor within the past 48 hours, or if such a&#xD;
             strategy for PCI involving a glycoprotein IIb/IIIa inhibitor is planned.&#xD;
&#xD;
          9. Taking maintenance thienopyridine therapy in the previous 5 days.&#xD;
&#xD;
         10. Known blood transfusion within the preceding 10 days.&#xD;
&#xD;
         11. Patients treated with non-steroidal anti-inflammatory drugs (NSAIDS) within the&#xD;
             previous 5 days.&#xD;
&#xD;
         12. Patients with known chronic liver disease.&#xD;
&#xD;
         13. Age greater than 75 years&#xD;
&#xD;
         14. Body weight less than 60 kg&#xD;
&#xD;
         15. History of stroke or transient ischemic attack&#xD;
&#xD;
         16. Surgery planned within 1 month&#xD;
&#xD;
         17. Patient likely to require coronary artery bypass grafting&#xD;
&#xD;
         18. Any significant medical condition that, in the investigator's opinion, may interfere&#xD;
             with the patient's optimal participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron Waksman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medstar Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>July 29, 2011</study_first_submitted>
  <study_first_submitted_qc>August 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2011</study_first_posted>
  <last_update_submitted>August 8, 2014</last_update_submitted>
  <last_update_submitted_qc>August 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platelet reactivity</keyword>
  <keyword>Genotyping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

